An anticancer agent
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Product Categories

Product Type

Biochemicals

Research Area

Cancer
Cell Cycle
G2/S
G2/M
DNA Damage and Repair

Nedaplatin

Item No. 29001

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(SP-4-3)-diammine[2-(hydroxy-κO)acetato(2-)-κO]-platinum
CAS Number
95734-82-0
Synonyms
  • NSC 375101
Molecular Formula
C2H8N2O3Pt
Formula Weight
303.2
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
Water: *soluble
SMILES
[NH3][Pt+2]([O-]C1=O)([O-]C1)[NH3]
InChi Code
InChI=1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1
InChi Key
GYAVMUDJCHAASE-UHFFFAOYSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    25 mg

    $95

    Add

    50 mg

    $168

    Add

    100 mg

    $316

    Add

    250 mg

    $739

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Nedaplatin is a derivative of cisplatin (Item No. 13119) with anticancer activity.1 Nedaplatin undergoes spontaneous hydrolysis to form platinum complexes that cross-link DNA resulting in apoptosis and cell death.2,3 It inhibits the growth of human NUGC-4 gastric and KSE-1 esophageal squamous carcinoma cells (IC50s = 4.6 and 3.4 μM, respectively) and inhibits S to G2 and G2/M to G1 cell cycle progression.4 Nedaplatin (44 mg/kg) decreases tumor volume and increases survival in a Lewis lung carcinoma syngeneic mouse model.1 Nedaplatin (40 mg/kg) also decreases tumor volume in an HNC-3 head and neck cancer mouse xenograft model.5 It exhibits reduced nephrotoxicity in rats compared with cisplatin.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Uchida, N., Takeda, Y., Hojo, K., et al. Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur. J. Cancer 34(11), 1796-1801 (1998).

    2. Alberto, M.E., Lucas, M.F.A., Pavelka, M., et al. The second-generation anticancer drug Nedaplatin: A theoretical investigation on the hydrolysis mechanism. J. Phys. Chem. B 113(43), 14473-14479 (2009).

    3. Hanada, K., Suda, M., Kanai, N., et al. Pharmacokinetics and toxicodynamics of oxaliplatin in rats: Application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives. Pharm. Res. 27(9), 1893-1899 (2010).

    4. Tanaka, R., Takii, Y., Shibata, Y., et al. In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines. Cancer Chemother. Pharmacol. 56(3), 279-285 (2005).

    5. Yamada, H., Maki, H., Takeda, Y., et al. Evaluation of combined nedaplatin and docetaxel therapy for human head and neck cancer in vivo. Anticancer Res. 26(2A), 989-994 (2006).